background: Debate exists regarding the effect of raised BMI on the outcome of pregnancies after assisted reproduction technology.
Introduction
The rising incidence of obesity is a serious worldwide health burden. In the UK and many European countries, over half of women of reproductive age are either overweight kg/m 2 ) or obese (BMI ≥ 30 kg/m 2 ) (International Obesity Task Force, 2002; Balen and Anderson, 2007) . Obesity has a profound detrimental impact on natural fertility (van der Steeg et al., 2008) . Obese women are three times more likely to be infertile (Rich-Edwards et al., 1994) . Obesity is also associated with a higher risk of pregnancy complications, including miscarriage, preeclampsia, gestational diabetes, induction of labour, operative delivery, fetal macrosomia and congenital anomalies (Catalano et al., 2006; Stothard et al., 2009) .
With regard to miscarriage, there is evidence that women who conceive spontaneously are at an increased risk of miscarriage not only if they are obese (Lashen et al., 2004) but also if they are overweight (Hamilton-Fairley et al., 1992) .
However, the impact of raised BMI on the miscarriage rate after assisted reproduction technology (ART) is less clear and the literature is inconsistent. While some studies have reported higher miscarriage rates after IVF in women with raised BMI (Fedorcsak et al., 2000 (Fedorcsak et al., , 2004 Wang et al., 2000; Veleva et al., 2008) , others have not found a significant effect of obesity on ART outcome (Winter et al., 2002; Styne-Gross et al., 2005; Dechaud et al., 2006; Bellver et al., 2007; Matalliotakis et al., 2008) .
It is difficult to compare these studies because of their clinical heterogeneity, varying thresholds for defining obesity and reporting outcomes. Furthermore, most of the studies assessed ART outcome in relation to BMI following transfer of multiple embryos at various stages of development, including more than one cycle per woman and did not adjust for important confounders (Maheshwari et al., 2007; McClamrock, 2008) . A recent meta-analysis (Metwally et al., 2008a) concluded that there was insufficient evidence to describe the effect of obesity on women conceiving after ART.
Blastocyst culture and transfer allows better selection of embryos with a higher implantation potential. Single blastocyst transfer (SBT) is associated with higher pregnancy and lower miscarriage rates compared with single cleavage-stage embryo transfer, probably related to both improved embryo selection and better embryo-endometrial synchronization (Papanikolaou et al., 2006 (Papanikolaou et al., , 2008 , thus providing an avenue for studying the effect of clinical variables on miscarriage rate (McClamrock, 2008) .
The purpose of this study was to assess the effect of BMI on miscarriage rate in women conceiving the following SBT in fresh and cryo-thawed IVF cycles after controlling for important confounding factors.
Materials and Methods
Between January 2006 and March 2010, 4642 embryo transfers following IVF, with or without ICSI were performed at the Assisted Conception Unit at Guy's and St Thomas' Hospital, London, UK. Of these 4642 embryo transfers, 3680 were in the stimulated (fresh) cycle and 962 were cryo-thawed embryo transfers. The overall pregnancy rate for this period was 45% per fresh embryo transfer (1641/3680) and 40% per cryo-thawed embryo transfer (383/962). Among the 4642 embryo transfers, 1215 were Day 5 fresh blastocyst transfers and 621 were Day 5 cryo-thawed blastocyst transfers. Of these, 621 (51%) were fresh SBT and 268 (43%) were cryo-thawed SBT.
Study inclusion criteria
Only fresh and cryo-thawed SBT resulting in the first pregnancy during the study period were included in the study. Women over the age of 40 years or those who had a BMI below 18.5 receiving an SBT were excluded from our study because of the association of these two factors with increased risk of miscarriage (Hourvitz et al., 2006; Lambers et al., 2007; Maconochie et al., 2007; Veleva et al., 2008) . No patient with a BMI above 35 (estimated to be 3% of patients seeking IVF treatment) was treated in our clinic during the study period (Balen and Anderson, 2007) . In addition, cycles involving PGD or the use of donated oocytes or embryos frozen for fertility preservation prior to cancer therapy were excluded. Pregnancies occurring in women with Mullerian duct anomalies or resulting in a monozygotic twin gestation were also excluded from the study (Bellver et al., 2003; Matias et al., 2007) .
Fresh IVF cycles
Our protocol for ovarian stimulation, IVF/ICSI and embryo culture has been described elsewhere (El-Toukhy et al., 2002; Khalaf et al., 2008) . Briefly, controlled ovarian stimulation was carried out using either the long GnRH agonist protocol (97%) or the GnRH antagonist protocol (3%) and recombinant FSH injections. The starting gonadotrophin dose was determined according to patient's age, previous response to ovarian stimulation and basal (Day 2 -4) FSH level and antral follicle count (AFC). HCG injection was given when the leading follicle(s) had reached more than 17 mm in diameter and oocyte retrieval was performed 36 h later. Culture of gametes and embryos was in SAGE culture media (Rochford Medical, Oxford, UK). Extended embryo culture to Day 5 was offered to women who had at least two 8-cell embryos with ,10% cytoplasmic fragmentation on Day 3 of in vitro culture. The quality of the blastocysts transferred was scored using the Gardner and Schoolcraft (1999) grading system. Women undergoing embryo transfer received progesterone supplementation in the form of micronized progesterone pessaries (Cyclogest, Shire Pharmaceuticals, Hants, UK) 400 mg twice a day from the day of oocyte retrieval up to 8 weeks gestation. All embryo transfers were carried out on Day 5 after IVF insemination or ICSI. Transferred blastocysts were recorded as high quality if, at the time of transfer, they had an expansion score of at least 3, type B for the inner cell mass and type B for trophectoderm (3BB) according to the Gardner and Schoolcraft (1999) blastocyst grading system. Surplus blastocysts were cryopreserved using a slow-freezing protocol employing 1,2-propanediol and 0.2 M sucrose as cryoprotectants (Kaufman et al., 1995) providing they had a quality of at least 3BB.
Cryo-thawed treatment cycles
Endometrial preparation and blastocyst thawing and transfer were carried out as described previously (El-Toukhy et al., 2009) . Briefly, all cryo-thawed blastocyst transfers were performed in medicated cycles. Estradiol valerate 6 mg orally daily (Climaval, Novartis Pharmaceuticals, Surrey, UK) was commenced on Day 2 of menstruation following pituitary suppression and continued for 13 -15 days, after which endometrial thickness was evaluated. If endometrial thickness was ,7 mm, the dose of Climaval was increased to 8 mg/day for a further 7 -12 days. When endometrial thickness had reached at least 7 mm, progesterone supplementation in the form of Cyclogest pessaries 400 mg twice daily was commenced and cryopreserved blastocysts were thawed rapidly and transferred on Day 6 of progesterone supplementation. Lysed or degenerate blastocysts and those that had lost over 50% of their cells were considered damaged and excluded from transfer. Blastocyst re-expansion status at the time of transfer was assessed and recorded. Following embryo transfer, hormonal supplementation was continued until 12 weeks gestation.
Outcome measures
The primary outcome measure of the study was the occurrence of a miscarriage. Miscarriage was defined as any pregnancy loss before 23 weeks gestation. Pregnancy was confirmed by a positive urine hCG test 11 days after blastocyst transfer. A clinical pregnancy was defined as the observation of a gestational sac on ultrasound scanning 5 weeks after embryo transfer. A chemical miscarriage was defined as pregnancy loss before ultrasound or histological evidence of a pregnancy, and clinical miscarriage was defined as pregnancy loss after ultrasound detection of a gestational sac or histological evidence of pregnancy on curettage or removal of an ectopic pregnancy. All ongoing clinical pregnancies were followed until delivery. All miscarriages were followed until urine hCG test was negative.
In order to study the influence of BMI on miscarriage rate, patients were grouped according to the WHO obesity classification (World Health Organization, 2000) , in which normal weight was defined as a BMI of 18.5 -24.9, overweight as a BMI of 25 -29.9 and obesity as a BMI ≥ 30. The BMI was measured for each woman by a trained nurse at the cycle scheduling visit within one month of starting treatment and calculated as weight in kilograms divided by the square of height in metres (kg/m 2 ).
Data collection and statistical analysis
Data for fresh and cryo-thawed embryo transfer cycles were prospectively collected and stored in a relational database. Information regarding patients' demographics and baseline characteristics, including age, BMI, ethnicity, duration and cause of infertility, previous history of pregnancy and miscarriage, smoking status, alcohol consumption over 14 units per week, basal (Day 2 -4) FSH level and AFC, presence of uterine fibroids, as well as fresh and cryo-thawed IVF cycle characteristics and outcomes was recorded.
Univariate analysis of the study outcome measure and associated clinical variables was performed using two sample t-test, chi-square or Fisher's exact test where appropriate. Multivariate logistic regression analysis was used to determine the independent effect of BMI on miscarriage rate after adjusting for important confounding variables. In the fresh cycles, these variables were age (Hourvitz et al., 2006; Veleva et al., 2008) , polycystic ovary syndrome (PCOS) as cause of infertility (Balen et al., 1993; van der Spuy and Dyer, 2004; Bahceci and Ulug, 2005) , previous history of miscarriage (Schieve et al., 2003; Kupka et al., 2004; Wang et al., 2004; Veleva et al., 2008) , smoking status (Hughes and Brennan, 1996; Winter et al., 2002) , the presence of uterine fibroids (Khaund and Lumsden, 2008) , duration of ovarian stimulation, number of oocytes retrieved (Fedorcsak et al., 2004) , quality of the blastocyst transferred (Winter et al., 2002; Richter et al., 2007) and having surplus embryos suitable for cryopreservation (Lambers et al., 2007) . In the frozen cycles, the confounding variables studied were age at cryopreservation (Yang et al., 2008) , PCOS as cause of infertility, previous history of miscarriage, endometrial thickness at the time of initiating progesterone supplementation and post-thaw blastocyst re-expansion (Yang et al., 2008) . Odds ratios (ORs) and their 95% confidence intervals (CIs) were calculated using the exact method. Statview software package for Macintosh (Statview 4.1, Abacus Concepts Ltd., Berkeley, CA, USA) was used for statistical analysis. A P-value of ,0.05 was considered statistically significant.
Written informed consent to treatment was obtained from each woman upon entering our IVF programme and before starting a cryo-thawed embryo transfer cycle. Because the present work did not involve either therapeutic interventions or change to our routine IVF protocols, it did not require additional approval from our institutional ethics committee.
Results
During the study period, a total of 413 women met the study inclusion criteria and conceived following SBT; 325 of these conceived after fresh day 5 blastocyst transfer and 88 conceived after cryo-thawed blastocyst transfer. Fifteen other women conceived during the same period after SBT, but were excluded from the study as they had a BMI of less than 18.5 (n ¼ 3), were over 40 years old (n ¼ 6), had a Mullerian duct anomaly (unicornuate uterus, one) or had a monozygotic twin gestation (n ¼ 5).
The overall miscarriage rate in the study population was 27% (113/413), with 8% (33/413) chemical miscarriage and 20% (80/413) clinical miscarriage rates.
There was no significant difference between the overall miscarriage rate in fresh (26%, 84/325) and cryo-thawed transfer cycles (33%, 29/88, OR ¼ 0.69, 95% CI 0.41 -1.14, P ¼ 0.15). However, when the study population were divided according to their BMI, the overall miscarriage rate was significantly higher in women who had a BMI of ≥25 (38%, 64/169) compared with those who had a normal BMI (20%, 49/244, OR ¼ 2.4, 95% CI 1.6 -3.8, P , 0.001). Furthermore, when the chemical miscarriages were excluded from the analysis, the clinical miscarriage rate was significantly higher in women who had a raised BMI of ≥25 (31%, 47/152) compared with those who had a normal BMI (15%, 33/228, OR ¼ 2.6, 95% CI 1.6-4.4, P , 0.001).
In women who had a raised BMI, the overall miscarriage rate after fresh (35%, 47/133) and cryo-thawed blastocyst transfer cycles (47%, 17/36) was not different statistically (OR ¼ 0.61, 95% CI 0.29 -1.3, P ¼ 0.20). The overall miscarriage rate was also comparable in overweight 
Fresh IVF treatment cycles
During the study period, 325 women conceived following fresh day 5 SBT with an overall miscarriage rate of (26%, 84/325). These 325 women were grouped according to their BMI: normal BMI (18.5-24.9, n ¼ 192) and raised BMI (≥25, n ¼ 133). The two groups were comparable in their demographic and baseline characteristics, except that anovulatory infertility related to PCOS was more common in women with raised BMI (Table I ). The two groups were also comparable in their IVF cycle characteristics except that women with raised BMI required longer duration of ovarian stimulation (Table II) .
Overall miscarriage rate
The overall miscarriage rate in women with raised BMI (35%, 47/133) was significantly higher compared with that in women who had normal BMI (19%, 37/192, OR: 2.3, 95% CI: 1.4-3.8, P ¼ 0.001).
Clinical miscarriage rate
Among the 325 women who conceived following fresh day 5 SBT, 20 women had a chemical miscarriage (11 in the normal BMI group and 9 in the raised BMI group). After exclusion of those 20 miscarriages, the clinical miscarriage rate in women with raised BMI (30.6%, 38/124) was significantly higher compared with that in women who had normal BMI (14.4%, 26/181, OR: 2.6, 95% CI: 1.4 -4.7, P ¼ 0.006). Among the 64 clinical miscarriages encountered after fresh day 5 SBT, three occurred at 13 -22 weeks gestation (i.e. second trimester pregnancy loss), all of which were in women with raised BMI.
When further subdividing the group of women who had a raised BMI into overweight , n ¼ 106) and obese (BMI ≥ 30, n ¼ 27), the overall miscarriage rate was comparable in these two subgroups [33% (35/106) and 44% (12/27), respectively, OR ¼ 0.64, 95% CI 0.27 -1.52, P ¼ 0.32], as was the clinical miscarriage To control for important confounding variables, BMI was employed in a multivariate logistic regression model with the following variables: age at treatment, PCOS as cause of infertility, history of previous miscarriage, smoking status, the presence of uterine fibroids, results of ovarian reserve testing, number of 8-cell embryos available on Day 3 and number of blastocysts available on Day 5, the transfer of a high-quality blastocyst and availability of surplus blastocysts suitable for cryopreservation. A BMI of ≥25 remained associated with a significantly higher risk of clinical miscarriage after adjusting for these variables (adjusted OR ¼ 2.7, 95% CI 1.5 -4.9, P ¼ 0.001).
Cryo-thawed treatment cycles
During the study period, 88 women conceived following cryo-thawed SBT, and the overall miscarriage rate was 33% (29/88). These 88 women were grouped according to their BMI: normal BMI (18.5-24.9, n ¼ 52) and raised BMI (≥25, n ¼ 36). The two groups were comparable in their baseline and cryo-thawed cycle characteristics (Tables III and IV) .
Overall miscarriage rate
The overall miscarriage rate in women with raised BMI (47%, 17/36) was significantly higher compared with that in women who had a normal BMI (23%, 12/52, OR ¼ 3.0, 95% CI 1.2-7.5, P ¼ 0.02).
Clinical miscarriage rate
Among the 88 women who conceived following cryo-thawed SBT, 13 women had a chemical miscarriage (5 in the normal BMI group and 8 in the raised BMI group). After exclusion of those 13 miscarriages, the clinical miscarriage rate in women with raised BMI (32%, 9/28) tended to be higher compared with that in women who had a normal BMI (15%, 7/47, OR: 2.7, 95% CI: 0.9-8.4, P ¼ 0.07). Among the 16 clinical miscarriages encountered after cryo-thawed SBT, one occurred between 13 and 22 weeks gestation (i.e. second trimester pregnancy loss), and was in the group of women with raised BMI.
When further subdividing the group of women who had a raised BMI into overweight (BMI 25 -29.9, n ¼ 30) and obese (BMI ≥ 30, n ¼ 6), the overall miscarriage rate was comparable between overweight and obese women [50% (15/30) versus 33% (2/6), OR ¼ 2.0, 95% CI 0.32 -12.6, P ¼ 0 previous miscarriage, smoking status, outcome of fresh cycle, endometrial thickness and post-thaw blastocyst re-expansion. A BMI of ≥25 remained associated with a significantly higher risk of clinical miscarriage after adjusting for these variables (adjusted OR ¼ 6.8, 95% CI 1.5-31.1, P ¼ 0.012).
Discussion
Miscarriage is a common pregnancy complication with significant medical and psychological consequences in affected couples (Lok and Neugebauer, 2007) . The present study is the first to examine the effect of BMI on miscarriage rate after SBT in women undergoing IVF treatment. The study results demonstrate that women who have a BMI between 25 and 35 are more than twice as likely to have a clinical miscarriage compared with women who have a normal BMI. This increased miscarriage risk was consistent after fresh and cryo-thawed blastocyst transfer cycles, although in the latter group the related CI was wider because of the smaller number of women included in that group. In the present study, 41% of women included were either overweight or obese. This high prevalence is comparable with the prevalence of increased BMI in women of reproductive age in the UK (Balen and Anderson, 2007) , and in all women receiving IVF treatment in our centre (unpublished audit data), further underscoring the importance of the study findings.
The overall miscarriage rate in the present study was 27% and the clinical miscarriage rate was 20%. It is often difficult to compare miscarriage rates in different studies owing to the variable definitions of miscarriage used and follow up duration employed in each study. The miscarriage rate also varies according to whether preclinical miscarriages (Bahceci and Ulug, 2005; Hourvitz et al., 2006) or cryo-thawed cycles were included (Veleva et al., 2008) . Nevertheless, the miscarriage rate in our study is in line with the 23 -32% miscarriage rates reported previously (Bungum et al., 2003; De Neubourg et al., 2004; Papnikolaou et al., 2005 Papnikolaou et al., , 2006 Hourvitz et al., 2006) The worldwide obesity epidemic underlines the importance of establishing reliably the reproductive health burden caused by raised BMI. Although numerous studies have investigated the risk of miscarriage in women with raised BMI following ART, a recent systematic review and meta-analysis found insufficient evidence to link raised BMI with a higher risk of miscarriage after ART (Metwally et al., 2008a) . The authors of that review identified significant clinical and methodological heterogeneity among published studies and described the ideal study to evaluate the relationship between raised BMI and miscarriage risk as one that is prospective, employs the WHO obesity classification, excludes women above the age of 40 years, includes miscarriages occurring up to 22 weeks gestation and considers the effect of possible confounders, including cause of infertility-particularly, the presence of PCOS (Metwally et al., 2008a) . Our study not only fulfils these criteria but also has addressed the shortcomings of the design in previous studies and adjusted for important confounding factors. The present study accounted for embryo quality, an important determinant of miscarriage risk, by the use of the SBT model. By replacing a single blastocyst on Day 5 after fertilization, using strict morphological criteria for assigning blastocyst grade (Gardner and Schoolcraft, 1999) and adjusting for blastocyst quality, our study aimed to minimize the influence of the embryonic developmental stage and quality on the risk of miscarriage (Richter et al., 2007) . Papanikolaou et al. (2006) demonstrated a lower miscarriage rate after blastocyst transfer compared with cleavage-stage embryo transfer, probably related to the ability to select for transfer the more competent embryos at the blastocyst stage. In addition, by replacing a single embryo in all the study participants and excluding monozygotic twin gestations, we removed the bias that could be introduced through the influence of multiple pregnancy on miscarriage rate (Matias et al., 2007) . Furthermore, we adjusted for the presence of a history of previous miscarriage, which is known to increase the risk of subsequent miscarriage (Kupka et al., 2004; Bianco et al., 2006) . Age, an important factor influencing the risk of miscarriage, was also accounted for in our study, particularly that the mean age of the women included in this study was 31.8 years and the majority (76%) were under 35 years of age. Moreover, we excluded women with a BMI below 18.5 in view of the evidence suggesting an increased risk of miscarriage in the presence of such low BMI (Maconochie et al., 2007; Veleva et al., 2008) .
Obesity and PCOS are closely related. Indeed, more women in the raised BMI group had anovulatory infertility secondary to PCOS (P ¼ 0.03). Although we adjusted for this factor in our analysis, it is important to note that there is evidence suggesting that the risk of miscarriage in patients with PCOS is not increased when BMI is accounted for (Wang et al., 2000; Bellver et al., 2003; Orvieto et al., 2009; Tehrani Nejod et al., 2011) .
The association between raised BMI and higher miscarriage rate is likely to be multi-factorial. A number of studies have suggested that being overweight or obese may have an adverse effect on oocyte or embryo quality (Fedorcsak et al., 2000 (Fedorcsak et al., , 2004 Wittemer et al., 2000; Carrell et al., 2001; Metwally et al., 2007; Qiao and Feng, 2011 ). This theory is not supported by our results. Despite a higher gonadotrophin requirement in the raised BMI group, there was no significant difference in markers of oocyte or embryo quality such as ovarian reserve, mean number of oocytes retrieved and fertilized normally, number of 8-cell embryos present on Day 3 and blastocysts available on Day 5 after insemination, blastocyst quality and number of blastocysts cryopreserved in the fresh IVF cycle. Furthermore, multivariate regression analysis showed that embryo quality was not related to the risk of miscarriage after fresh IVF/ICSI. Likewise, markers of cryo-thawed embryo viability, namely post-thaw blastocyst survival and re-expansion rates, were comparable in the two cryo-thawed embryo transfer groups. These results concur with earlier studies that did not find evidence of alteration in oocyte or embryo quality in overweight or obese women compared with women having normal BMI (Wang et al., 2000; Bellver et al., 2003 Bellver et al., , 2010 Veleva et al., 2008; Vilarino et al., 2011) .
It is likely that the increased miscarriage rate associated with raised BMI is related (wholly or in part) to endometrial dysfunction (Fedorcsak et al., 2000; Metwally et al., 2007) . Bellver et al. (2003) examined IVF outcome in recipients of donated oocytes and reported a higher miscarriage rate in obese recipients irrespective of the donor's BMI. More recently, Landres et al. (2010) analysed the karyotype of first trimester miscarriages in over 200 women under the age of 40 years and reported a propensity of euploid miscarriages among women with a BMI of ≥25 compared with women of the same age with normal BMI, pointing to the role of an endometrial effect.
Raised BMI is known to be associated with insulin resistance, which in turn is an independent risk factor for spontaneous miscarriage, both after natural conception (Craig et al., 2002) and after ART treatment (Tian et al., 2007) . The underlying mechanism of such an effect is thought to involve the reduced expression of endometrial glycodelin and insulin growth factor binding protein 1, both of which regulate implantation (Giudice, 2006) . Furthermore, receptors of leptin, a hormone produced mainly in adipose tissue, are expressed in the secretory endometrium, where they regulate endometrial angiogenesis (Bouloumie et al, 1998) and thus may influence implantation (Gonzalez et al., 2000; Mitchell et al., 2005) . Altered plasma leptin levels and the leptin-resistant state associated with obesity (Enriori et al, 2006) have been shown to be associated with impaired trophoblastic invasion (Castellucci et al., 2000; Kawamura et al., 2003) and early miscarriage (Lage et al., 1999) . In addition, plasma levels of leptin correlate with BMI (Andrico et al., 2002) and high leptin levels could exacerbate insulin resistance (Veleva et al., 2008) , thus predisposing to miscarriage. Other endocrine disruptions implicated in endometrial dysfunction associated with raised BMI include alteration in steroid hormone metabolism and adipose-tissue-dependent secretion of cytokines, such interleukin-6, leukaemia inhibitory factor and tumour necrosis factor-a (ESHRE Capri Workshop Group, 2006; Metwally et al., 2008b; Samy et al., 2009) .
Age and reproductive history are non-modifiable factors influencing the risk of miscarriage, whereas raised BMI is modifiable. The present study shows that not only obese but also overweight women have an increased risk of miscarriage after ART treatment. This finding is in line with previous studies that studied miscarriage risk at a BMI of 25 -29.9 (Hamilton-Fairley et al., 1992; Bellver et al., 2007) . Although there was no significant difference in the miscarriage rate between overweight and obese women in the present study, our results could not exclude a linear relationship between increasing BMI and risk of miscarriage, as previously suggested (Fedocksak et al., 2004; Bellver et al., 2010) . This is probably related to the small number of obese women in our study (8% of study population) and absence of data on women with a BMI over 35-a group of patients who remain under-represented in current literature (Maheshwari et al., 2007) . The lack of such information renders restricting access to fertility services on the basis of different BMI thresholds highly contentious (Maheshwari, 2010) . Instead, our results should pave the way for widespread adoption and implementation of effective weight management strategies to guide infertile patients pursuing weight reduction in order to reduce the physical and psychological burden of miscarriage (Clark et al, 1998; Metwally et al., 2009) .
In conclusion, this study demonstrates clearly that raised BMI is independently associated with higher miscarriage rate after IVF treatment. This information should be used in counselling patients on the reproductive consequences of raised BMI prior to starting an IVF cycle. Concurrently, appropriate measures should be taken to develop an effective weight management service for overweight and obese women intending to embark on IVF treatment.
